ReviewExpert review of anti-infective therapy2016
Management of relapsing Plasmodium vivax malaria.
Review in Expert review of anti-infective therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Prevalence of malaria and its major parasite species in Bangladesh: a systematic review and meta-analysis.Malaria journal · 2026Pooled it
- In vivo efficacy of anti-malarial drugs against clinical Plasmodium vivax malaria in Ethiopia: a systematic review and meta-analysis.Malaria journal · 2021Pooled it
- Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.The Cochrane database of systematic reviews · 2019Pooled it
- The Vivax Surveyor: Online mapping database for Plasmodium vivax clinical trials.International journal for parasitology. Drugs and drug resistance · 2017Pooled it
- Analytical dilemmas in assessing efficacy of radical cure of vivax malaria.The Lancet regional health. Southeast Asia · 2026Article
- Risk perceptions of high-dose primaquine and tafenoquine amongBMJ global health · 2026Article
- Presumed Relapse of Plasmodium vivax Malaria Presenting With Thrombocytopenia in a Non-endemic Area: A Case Report.Cureus · 2026Article
- Efficacy of primaquine-chloroquine combination onParasite epidemiology and control · 2026Article
- Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.PLoS neglected tropical diseases · 2026Article
- Optimal control and cost-effectiveness analysis of PfSPZ vaccination and indoor residual spraying in malaria transmission: a case study in Keerom.Frontiers in public health · 2026Article
- Understanding imported malaria in western Nepal: Implications for malaria control and elimination.PLOS global public health · 2026Article
- Enhancing unique identification of patients with malaria using biometric fingerprinting in Papua, Indonesia.Malaria journal · 2025Article
- Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study.Malaria journal · 2025Observational
- Experimental models of liver-stage malaria: Progress, gaps, and challenges.PLoS pathogens · 2025Review
- Acute Rickettsiosis TriggeringPathogens (Basel, Switzerland) · 2025Review
- Impact of CYP2D6, MAOA, and UGT2B7 genetic variants on recurrence of Plasmodium Vivax in the Brazilian Amazon.Scientific reports · 2025Article
- Synthetic account on indoles and their analogues as potential anti-plasmodial agents.Molecular diversity · 2025Review
- Recent Advancement in Drug Development for Treating Malaria using Herbal Medicine and Nanotechnological Approach.Current pharmaceutical design · 2025Review
- Genomic analysis of global Plasmodium vivax populations reveals insights into the evolution of drug resistance.Nature communications · 2024Article
- Associations between weather andmedRxiv : the preprint server for health sciences · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionRelapses are important contributors to illness and morbidity in Plasmodium vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria. A review was conducted with publications in English, French, Portuguese and Spanish using the search terms 'P. vivax' and 'relapse'. AREAS COVERED: Hypnozoites causing relapses may be activated weeks or months after initial infection. Incidence and temporal patterns of relapse varies geographically. Relapses derive from parasites either genetically similar or different from the primary infection indicating that some derive from previous infections. Malaria illness itself may activate relapse. Primaquine is the only widely available treatment for radical cure. However, it is often not given because of uncertainty over the risks of primaquine induced haemolysis when G6PD deficiency testing is unavailable. Recommended dosing of primaquine for radical cure in East Asia and Oceania is 0.5 mg base/kg/day and elsewhere is 0.25 mg base/kg/day. Alternative treatments are under investigation. Expert commentary: Geographic heterogeneity in relapse patterns and chloroquine susceptibility of P. vivax, and G6PD deficiency epidemiology mean that radical treatment should be given much more than it is today. G6PD testing should be made widely available so primaquine can be given more safely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.